+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sandoz AG - logo

Sandoz is recognized as the global leader in biosimilars and generic antibiotics, dermatology and transplantation medicines. It also holds leading global positions in areas ranging from generic cardiovascular, central nervous system (CNS), pain and ophthalmology to oncology, respiratory and hormonal therapeutics. Its products are sold in more than 160 countries, and reach more than 500 million patients. The company was founded in 1946 and is based in Princeton, New Jersey.

From
Capecitabine Global Market Report 2024 - Product Thumbnail Image

Capecitabine Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Etanercept - Biosimilar Insight, 2024 - Product Thumbnail Image

Etanercept - Biosimilar Insight, 2024

  • Report
  • August 2024
  • 60 Pages
  • Global
From
Levofloxacin Global Market Report 2024 - Product Thumbnail Image

Levofloxacin Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Infliximab Drug Market - Global Forecast Report 2023-2031 - Product Thumbnail Image

Infliximab Drug Market - Global Forecast Report 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Paclitaxel Injection Global Market Report 2024 - Product Thumbnail Image

Paclitaxel Injection Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Infliximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Infliximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Humira Drug Global Market Report 2024 - Product Thumbnail Image

Humira Drug Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031 - Product Thumbnail Image

HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
From
Adalimumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Adalimumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Loading Indicator